Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glucocorticoid-resistant human lymphoma cell line

A technology of lymphoma cells and corticosteroids, applied in the field of human lymphoma cell lines, can solve the problems of lymphoma glucocorticoid resistance, lack of experimental platform and other problems

Inactive Publication Date: 2012-11-07
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the glucocorticoid-resistant cell line of human diffuse large B-cell lymphoma, and the study of glucocorticoid resistance in lymphoma lacks a good experimental platform

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glucocorticoid-resistant human lymphoma cell line
  • Glucocorticoid-resistant human lymphoma cell line
  • Glucocorticoid-resistant human lymphoma cell line

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 Establishment of Toledo / DEX cells

[0020] The present invention adopts human diffuse large B-cell lymphoma Toledo cell strain as source cells, and the human diffuse large B-cell lymphoma Toledo cell strain is derived from the peripheral blood of a female patient with diffuse large B-cell lymphoma, and the patient received a large dose of Brain metastases occurred after chemotherapy and bone marrow hematopoietic stem cell transplantation. It is a typical case of refractory lymphoma. It was established in 1990, ATCC number: CRL-2631, and was introduced and preserved by the Department of Hematology, Huashan Hospital affiliated to Fudan University. The present invention adopts a long-term intermittent low-dose glucocorticoid incremental induction method to induce the glucocorticoid-resistant human lymphoma cell line Toledo / DEX, which has been preserved on March 4, 2011. The depository unit: China Microbiological Culture Preservation Management Committee Common Mic...

Embodiment 2

[0024] Example 2 drug resistance test

[0025] Show through experiment, Toledo / DEX cell of the present invention can contain DEX 1.024 * 10 -5 Stable growth in the concentration of M, the resistance to DEX increased by 1227 times.

[0026] Table 1 Toledo / DEX cell drug resistance spectrum analysis

[0027]

[0028] Note: * indicates statistical significance (P<0.05).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention belongs to the field of microbial animal cell lines, and specifically relates to a human diffuse large B-cell lymphoma glucocorticoid-resistant cell line Toledo / DEX having a glucocorticoid-resistant potential. The GR [alpha] expression level of the Toledo / DEX cell strain of the invention is below source cells, and the drug-resistant multiple of the cell strain for dexamethasone is higher than the source cells. The source cells are the diffuse large B-cell lymphoma cell line. The cell line is the first case of the human diffuse large B-cell lymphoma glucocorticoid-resistant cell line having the glucocorticoid-resistant potential at home and abroad. The cell line shows that establishing lymphoma drug-resistant cell lines by a long-term, intermittent, low-dose glucocorticoid increment induction method is practically feasible. The establishment of the Toledo / DEX cell line provides an experimental platform for subsequent glucocorticoid drug-resistant mechanisms and reversal.

Description

technical field [0001] The invention belongs to the field of microbial animal cell lines, and in particular relates to a human lymphoma cell line with glucocorticoid-resistant potential. Background technique [0002] According to the results of the third national cause of death survey published by the Ministry of Health, malignant tumors have become the first cause of death among urban residents in China. Malignant tumors have seriously threatened people's lives. In recent years, the incidence of non-Hodgkin's lymphoma has also increased year by year. According to the American Cancer Survey data, there were 65,980 new cases of non-Hodgkin's lymphoma in 2009, and the incidence rate of female tumors rose to the fifth place. Domestic statistics are generally similar to those of foreign countries. Diffuse large B-cell lymphoma is one of the most common types of non-Hodgkin lymphoma and is aggressive, accounting for 30%-40% of non-Hodgkin lymphoma. CD 20 The application of b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/09C12Q1/02C12R1/91
Inventor 许小平谭微陈波斌马燕韩天洁
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com